NEW YORK, September 23, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Halozyme Therapeutics, Inc. (NASDAQ: HALO),
Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena
Biopharma, Inc. (NASDAQ: GALE), AMAG Pharmaceuticals,
Inc. (NASDAQ: AMAG), EXACT Sciences Corporation (NASDAQ:
EXAS). On Tuesday, September 22,
2015, Nasdaq ended at 4,756.72, down 1.50%, Dow Jones
declined 1.09%, to finish the day at 16,330.47, and the S&P
closed at 1,942.74, down 1.23%. Register for your complimentary
reports at the links given below.
--
Halozyme Therapeutics Inc
--
Halozyme Therapeutics Inc's stock edged lower by 4.61% to close
Tuesday's session at USD 17.38. The
company's shares oscillated between USD
17.07 and USD 18.42. The stock recorded a trading volume of
1.78 million shares, which was above its 50-day daily average
volume of 1.38 million shares and above its 52-week average volume
of 1.48 million shares. Over the last three days, Halozyme
Therapeutics Inc's shares have declined by 9.99% and in the past
one week it has moved down 4.82%. Furthermore, over the last three
months, the stock has lost 20.35% and in the past six months, the
shares have picked up 25.13%. The stock is at a price to book ratio
of 44.21 against a historical PB ratio of 29.34. Additionally, the
stock is trading at a price to sales ratio of 20.75. Sign up and
read the free notes on HALO at:
http://www.aciassociation.com/HALO.pdf
--
Celldex Therapeutics Inc
--
The stock of Celldex Therapeutics Inc lost 2.81% to close
Tuesday's session at USD 13.83. The
shares of the company moved in the range of USD 13.45 and USD
14.32. A trading volume of 1.70 million shares was recorded,
which was lower than its 150-day daily average volume of 1.89
million shares and below its 52-week average volume of 2.14 million
shares. Over the last five days, Celldex Therapeutics Inc's shares
have declined by 11.80% and in the past one month, it has gained a
momentum of 2.60%. Additionally, over the last three months, the
stock has declined 47.33% and in the past six months, the shares
have registered a loss of 50.91%. The stock is trading at a price
to book ratio of 3.94 against the historical PB ratio of 7.72.
Register for free on ACI Association and access the latest research
on CLDX at: http://www.aciassociation.com/CLDX.pdf
--
Galena Biopharma Inc
--
Galena Biopharma Inc's stock decreased by 2.66% to close
Tuesday's session at USD 1.83. The
company's shares fluctuated in the range of USD 1.79 and USD
1.92. A total of 1.68 million shares exchanged hands, which
surpassed its 50-day daily average volume of 1.63 million shares
and was below its 52-week average volume of 2.26 million shares.
Over the last three days, Galena Biopharma Inc's shares have
advanced 1.67% and in the past one week it has moved up 2.23%.
Furthermore, over the last three months, the stock has lost 5.67%
and in the past six months, the shares have picked up 24.07%. The
complete research on GALE is available for free at:
http://www.aciassociation.com/GALE.pdf
--
AMAG Pharmaceuticals Inc
--
AMAG Pharmaceuticals Inc's stock slipped by 3.20% to close
Tuesday's session at USD 44.48. The
company's shares oscillated between USD
43.84 and USD 46.48. The stock recorded a trading volume of
1.63 million shares, which was above its 50-day daily average
volume of 0.95 million shares and above its 52-week average volume
of 0.76 million shares. Over the last five days, AMAG
Pharmaceuticals Inc's shares have declined by 12.15% and in the
past one month, it has lost 27.92%. In addition, over the last
three months, the stock has lost 39.32% and year to date, the
shares have picked up 4.36%. Further, the stock is trading at a
price to earnings ratio of 7.49 and a price to book ratio of 1.93.
This compares to a historical PE ratio of 7.92 and the historical
PB ratio of 2.37. Free in-depth research on AMAG is available at:
http://www.aciassociation.com/AMAG.pdf
--
Exact Sciences Corp
--
Exact Sciences Corp's stock advanced 2.54% to close Tuesday's
session at USD 19.00. The share price
vacillated between USD 17.87 and USD
19.08. The stock recorded a trading volume of 1.52 million
shares, which was above its 50-day daily average volume of 1.42
million shares and below its 52-week average volume of 1.65 million
shares. Over the last three days Exact Sciences Corp's shares have
declined by 4.23% and in the past one week it has moved down 3.99%.
Moreover, in the last six months, the stock has lost 18.42% and
year to date, the shares have shed 30.76%. The stock is trading at
a price to book ratio of 7.53 and the historical PB ratio of 8.42.
The complimentary notes on EXAS can be downloaded in PDF format at:
http://www.aciassociation.com/EXAS.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com